Physician profile
Robert Setlik
NPI 1487635678
$5,756.72
in general payments reported to CMS, 2019-2025
48 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $1,843 · 2023: $1,395 · 2024: $1,272 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.24 |
| Education | $319.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $562.65 | 2021-2025 | Padcev |
| Novartis Pharmaceuticals Corporation | $435.76 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $377.35 | 2021-2024 | Opdivo, Abecma, Reblozyl |
| Merck Sharp & Dohme LLC | $373.01 | 2022-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $371.02 | 2022-2025 | Enhertu, Tagrisso, Calquence |
| Janssen Biotech, INC. | $348.18 | 2022-2025 | Talvey, Darzalex, Rybrevant |
| Pfizer INC. | $286.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $253.38 | 2022-2024 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $212.62 | 2022-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $185.68 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $181.35 | 2022-2024 | Clonoseq |
| Daiichi Sankyo INC. | $151.69 | 2022-2023 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $150.09 | 2022-2024 | Libtayo |
| Seagen INC. | $141.90 | 2022-2023 | Tukysa, Adcetris |
| Genzyme Corporation | $138.25 | 2023-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $137.90 | 2021-2025 | Brukinsa |
| Abbvie INC. | $135.48 | 2023-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $129.65 | 2022-2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $123.77 | 2022-2025 | Ninlaro, Iclusig, Fruzaqla |
| Genentech USA, INC. | $110.49 | 2022-2023 | Phesgo, Perjeta, Lunsumio |
| Incyte Corporation | $93.41 | 2022-2025 | Monjuvi, Pemazyre |
| Pharmacosmos Therapeutics INC. | $87.76 | 2022-2025 | Monoferric |
| Pharmaessentia USA Corporation | $87.35 | 2022-2025 | Besremi |
| Lilly USA, LLC | $76.30 | 2021-2023 | Jaypirca, Retevmo, Verzenio |
| Array Biopharma INC | $69.93 | 2022-2024 | Mektovi, Braftovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $65.10 | 2021-2024 | |
| Amgen INC. | $51.25 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Mirati Therapeutics, INC. | $37.36 | 2023 | Krazati |
| Foundation Medicine, INC. | $35.73 | 2022-2023 | |
| Servier Pharmaceuticals LLC | $34.84 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $26.03 | 2025 | Danziten |
| Dendreon Pharmaceuticals LLC | $25.09 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.73 | 2025 | Adstiladrin |
| Jazz Pharmaceuticals INC. | $20.52 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.06 | 2023 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $19.82 | 2023 | Imbruvica |
| Syndax Pharmaceuticals, INC. | $19.19 | 2025 | Revuforj |
| Exelixis INC. | $18.91 | 2024 | Cabometyx |
| Tg Therapeutics, INC. | $17.67 | 2022 | |
| Sandoz INC. | $17.32 | 2022 | |
| Cti Biopharma Corp. | $16.50 | 2023 | Vonjo |
| Alnylam Pharmaceuticals INC. | $15.40 | 2024 | Givlaari |
| Accord Healthcare, INC. | $15.18 | 2024 | |
| Taiho Oncology, INC. | $14.20 | 2022 | |
| Tactile Systems Technology INC | $14.00 | 2022 | |
| Adc Therapeutics America, INC. | $13.55 | 2022 | |
| Tersera Therapeutics LLC | $13.44 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Setlik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.